I challenge you to find any value in this coverage of LabCorp.
They remind me of the old-line pharma companies in their formative years.
These healthcare stocks may not be in ‘hot’ sectors, but they are outpacing the market nonetheless.
Becton Dickinson’s P/E ratio is far below the 10-year median, and its payout has become quite generous.
At least three Fibonacci time cycles support a bullish stance against this recent low.
You have to like a stock that goes higher on disappointment.
As M&A action heats up in the sector, consider two names that could shape up to be prime targets.
Even given the sharp climb in these stocks, they likely still have room to run.
Under the surface, I'm not seeing the sort of frenzied buying that the numbers suggest.
If the healthcare plan stands, these names stand to reap rich rewards.